WaveMan
WaveMan · Company
ADIL · Adial Pharmaceuticals, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

ADIL Adial Pharmaceuticals (ADIL) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001513525
Quote by TradingView
SEC filings
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
8
13F, latest reported quarter

What the filings say about ADIL

Insiders, 180 days
+$106.3K net bought
1 buyer

Adial Pharmaceuticals insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, ADIAL PHARMACEUTICALS, INC. insiders bought a net $106.3K of stock across 13 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Coastlands Capital LP
BUY
2026-07-16 SEC
1,233
$3.4K
+32.5%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Jul 14, 2026.
  • +42.7% median (+43.3% mean) 90-day return after 4 previous buys.
  • The trade is 0.3% of the 388,308 shares held after it.
  • No other insider bought within 30 days.
  • 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Coastlands Capital LP bought about $3.4K of ADIL on Jul 16, 2026; 8 funds added in the latest 13F quarter.
Coastlands Capital LP
BUY
2026-07-16 SECtraded 2026-07-14
2,000
$5.3K
+32.5%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Jul 10, 2026.
  • +42.8% median (+47.1% mean) 90-day return after 3 previous buys.
  • The trade is 0.5% of the 387,075 shares held after it.
  • No other insider bought within 30 days.
  • 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Coastlands Capital LP bought about $5.3K of ADIL on Jul 14, 2026; 8 funds added in the latest 13F quarter.
Coastlands Capital LP
BUY
2026-07-13 SECtraded 2026-07-10
1,700
$4.6K
+40.0%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Jul 9, 2026.
  • +49.2% median (+49.2% mean) 90-day return after 2 previous buys.
  • The trade is 0.4% of the 385,075 shares held after it.
  • No other insider bought within 30 days.
  • 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Coastlands Capital LP bought about $4.6K of ADIL on Jul 10, 2026; 8 funds added in the latest 13F quarter.
Coastlands Capital LP
BUY
2026-07-13 SECtraded 2026-07-09
10,053
$28.0K
+40.0%
Context
  • 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Jun 29, 2026.
  • The trade is 2.6% of the 383,375 shares held after it.
  • No other insider bought within 30 days.
  • 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Coastlands Capital LP bought about $28.0K of ADIL on Jul 9, 2026; 8 funds added in the latest 13F quarter.
Coastlands Capital LP
BUY
2026-07-01 SECtraded 2026-06-29
25,000
$65.0K
+27.9%
Context
  • First Form 4 purchase or sale (code P or S) here by this insider on our record.
  • The trade is 6.7% of the 373,322 shares held after it.
  • No other insider bought within 30 days.
  • 8 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Insider Coastlands Capital LP bought about $65.0K of ADIL on Jun 29, 2026, the largest insider purchase at the company on our record; 8 funds added in the latest 13F quarter.
13 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 8 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$106.3K over 180 days
+$106.3K of it by a 10%+ holder
more than 77% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
8 funds bought in last quarter
below 89% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
8.7% of the float short (float per yahoo 2026-10-26) · 4.3 days to cover · settled 2026-09-30
more than 60% of Pharma & Biotech
What changed in the last 30 days
Oct 28Insider buying stopped: no purchases in 90 days after 5 in the prior 90
Why it matters
The absence is the signal: 5 purchases in one 90-day window and none in the next is a change of behaviour, not a filing.

Watch ADIL

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-58.8%12M
-85%-55%-25%+6%2025-102025-122026-022026-042026-062026-082026-10 2026-06-29 · Coastlands Capital LP bought $65.0K2026-07-09 · Coastlands Capital LP bought $28.0K2026-07-14 · Coastlands Capital LP bought $5.3K2026-07-10 · Coastlands Capital LP bought $4.6K2026-07-16 · Coastlands Capital LP bought $3.4K
Insider buy
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns ADIL: institutional holders (13F)

13F holdings, latest reported quarter
Stonepine Capital Management, LLC
727,563 sh
$1.6M
JANE STREET GROUP, LLC
32,119 sh
$82.2K
CITADEL ADVISORS LLC
29,547 sh
$75.6K
UBS Group AG
19,147 sh
$49.0K
StoneX Group Inc.
19,699 sh
$35.7K

Congress trades in ADIL

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

ADIL planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

ADIL mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Fidelity Extended Market Index Fund
$56.6K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$924 position · as of 2026-06-30
0.0%
Fidelity Total Market Index Fund
$744 position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
1 registered trials, 0 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
1
Phase 3
0 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders are net buyers of their own stock.
The record shows a net $106.3K bought by insiders over 180 days, 8 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

ADIL financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$11.2M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
n/a
average equity is zero or negative
Return on assets
-44,457,473%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-390.2%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
n/a
no debt line filed
FCF yield
-114.9%
TTM free cash flow over market value at close 2026-10-27
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$7.8M-$8.3M-$6.9M-$10.9M
Net income-$8.0T-$13.2T-$5.1T-$12.7M
EPS (diluted)-11.93-68.01-3.60-12.71
Operating cash flow-$6.5M-$6.9M-$6.8M-$11.2M
Cash$5.9M$3.8M$2.8M$4.0M
Buybacksn/an/a$1.7Kn/a
SEC XBRL, fiscal years, as known on 2026-10-28

ADIL Stock Sonar score 4/7 axes

Find similar shapesCompare

ADIL ranks highest on insider conviction (66th percentile) and risk and compliance (44th), and lowest on profitability (2nd), among Pharma & Biotech peers.

Profitability
2
Inputs
  • Return on equityaverage equity is zero or negative
  • Return on assets-44457473% · 0 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-390.2% · 4 pct, sector of 576
Insider conviction
66
Inputs
  • Net Form 4 buying (codes P and S), 180d$106K · 76 pct, sector of 428
  • Insider buyers, 180d1 · 56 pct, sector of 437
Institutional and government
8
Inputs
  • Funds adding, latest quarter8 · 11 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quarters$40K · 6 pct, sector of 133
Risk and compliance
44
Inputs
  • Short interest, % of float+8.7% · 44 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

ADIL filings, in plain words

Are Adial Pharmaceuticals insiders buying or selling ADIL?

In the 180 days to 2026-10-28, Adial Pharmaceuticals insiders were net buyers, a net $106.3K across purchases and sales reported on Form 4, by 1 buyer.

Read the full summary

In the 180 days to 2026-10-28, Adial Pharmaceuticals insiders were net buyers of ADIL, a net $106.3K across purchases and sales reported on Form 4 by 1 buyer. Most of that figure, $106.3K, came from a holder of 10% or more rather than an officer or director. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies